首页> 外文期刊>Diabetes research and clinical practice >The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance.
【24h】

The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance.

机译:高血压患者中visfatin和HOMA-IR的关系,以及降压药对胰岛素抵抗性高血压患者中visfatin和HOMA-IR的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To investigate the correlation between serum visfatin and insulin resistance (IR) in non-diabetic essential hypertensive (EH) patients with and without IR, and to evaluate the effect of antihypertensive treatment on serum visfatin and IR in these patients. METHODS: A total of 81 non-diabetic EH patients, including 54 with IR and 27 without IR, were enrolled. After two weeks wash-out, patients with IR were randomly assigned to telmisartan (group T) or amlodipine (group A) for 6 months. Blood samples were taken before and after treatment for measurement of routine biochemical parameters, visfatin and insulin resistance (measured by HOMA-IR). RESULTS: Visfatin was independently correlated with HOMA-IR (r=0.845, P=0.000). After 6 months of treatment, both drugs lowered HOMA-IR, more significantly so in group T than group A (P=0.010). Serum visfatin levels increased in group T but decreased in group A. CONCLUSION: Serum visfatin levels were higher in non-diabetic EH patients with IR compared with those without IR. Visfatin is independently correlated with HOMA-IR. Telmisartan lowers HOMA-IR to a greater extent than amlodipine. Interestingly, serum visfatin increased with telmisartan yet decreased with amlodipine treatment.
机译:目的:探讨有无IR的非糖尿病原发性高血压(EH)患者血清visfatin与胰岛素抵抗(IR)的相关性,并评价降压治疗对这些患者的血清visfatin和IR的影响。方法:共纳入81例非糖尿病性EH患者,包括54例IR患者和27例IR患者。冲洗两周后,IR患者被随机分配至替米沙坦(T组)或氨氯地平(A组)6个月。在治疗前后采集血样,以测量常规生化参数,visfatin和胰岛素抵抗(通过HOMA-IR测量)。结果:Visfatin与HOMA-IR独立相关(r = 0.845,P = 0.000)。经过6个月的治疗,两种药物均降低了HOMA-IR,与A组相比,T组的降低更为明显(P = 0.010)。 T组血清visfatin水平升高,而A组下降。结论:IR非糖尿病EH患者的血清visfatin水平高于IR非糖尿病患者。 Visfatin与HOMA-IR独立相关。替米沙坦比氨氯地平降低HOMA-IR的程度更大。有趣的是,替米沙坦使血清visfatin增加,而氨氯地平治疗使血清visfatin减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号